Postoperative Pulmonary Complications in Abdominal Surgery
Recruitment status was: Not yet recruiting
Incidence of Postoperative Pulmonary Complications (PPCs) varies from 2% to 19%, according to the population under examination and the criteria used to define pulmonary complications. There is no univocal definition of PPCs. Usually physicians associate atelectasis, respiratory insufficiency, pneumonia, bronchospasm, necessity to reintubate. Moreover the evaluation of risk factors has become difficult.
The endpoint of this study is to determine the actual incidence of respiratory postoperative complications in patients undergoing general anesthesia for major abdominal surgery (general surgery, gynecology, urology).
This is an observational, descriptive, prospective, multicentric study. Investigators are going to enroll all the patients matching the inclusion criteria and follow them until discharge (clinical phase). Then they will be followed up until one year later.
Postoperative Pulmonary Complications
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Postoperative Pulmonary Complications in Major (Abdominal) Surgery: a Multicenter Study|
|Study Start Date:||January 2013|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
INTRODUCTION Pulmonary Postoperative Complications (PPCs) are among the most common causes of adverse events in the perioperative period and can determine a significant increase of mortality risk in hospitalization time.
Incidence of PPCs varies from 2% to 19%, according to the population under examination and the criteria used to define pulmonary complications. There is no univocal definition of PPCs. Usually physicians associate atelectasis, respiratory insufficiency, pneumonia, bronchospasm, necessity of tracheal reintubation. Moreover, the evaluation of risk factors is becoming increasingly difficult. Many aspects linked to the patient's conditions and postoperative anesthesiologic management have been demonstrated to influence the risk of developing PPCs. (with the endorsement of European Society of Anesthesiology) proposed a risk index based on seven perioperative parameters to predict PPCs probability.
Furthermore, patients who survive after pulmonary complications will still suffer from functional reductions and are at risk of having a decrease in medium and long-term survival.
PRIMARY END POINT To determine the actual incidence of respiratory postoperative complications in patients undergoing general anesthesia for major abdominal surgery (general surgery, urology, gynecology).
Respiratory complications are: pneumonia, respiratory insufficiency 8,9, pleural effusion, pneumothorax, atelectasia, ab ingestis pneumonia, necessity of oxygen supply, non invasive mechanical ventilation (NIMV) or tracheal reintubation.
SECONDARY END POINTS
- postoperative incidence of necessity of tracheal reintubation
- duration of mechanical ventilatory support
- postoperative incidence of infections
- postoperative incidence of PostOperative Residual Curarization (PORC)
- postoperative incidence of cardiovascular complications
- postoperative outcome (30, 60 days and one year later)
- time of hospital stay, hospital mortality
- necessity of admission to ICU and ICU length of stay
Duration of the clinical phase: hospitalization (data collection: two hours after discharge from the operating room, then from the first, up to the fifth postoperative day) Duration of follow-up after hospitalization (follow up period): 30 days - 60 days - 1 year.
RECRUITMENT AND MONITORING PROCEDURES All patients scheduled for elective major abdominal surgery, urologic surgery or major gynecological surgery under general anaesthesia will be enrolled in this study.
Patients will be enrolled over a 15 days period, after that, if the sample would be too small, another 15 days enrollment period will be repeated.
During the preoperative evaluation, the anesthesiologist will expose the study protocol to all patients who will match the inclusion criteria. The informed consent will be obtained.
Patients will be monitored in the postoperative period and will receive, standard postoperative care, as directed by the clinical teams and if indicated, antibiotics, diuretics, oxygen therapy and every therapy according to the underlying disease. Medical and nursing staff will monitor peripheral oxygen saturation in the origin ward.
In every center a researcher will evaluate the enrolled patients daily, checking for peripheral oxygen saturation, arterial pressure, heart rate, respiratory rate, body temperature and pain assessment (NRS scale).
Patient's clinical status until the hospital discharge will be reported on case report forms (CRFs). Every intraoperative parameter (like drugs used, the need of blood transfusion, fluid management and fluid balance at the end of surgery) will be recorded.
Treatments and therapy will be continued according to clinicians decision and will be recorded in the CRF.
The decision to start an oxygen therapy or a ventilatory support (invasive or non-invasive) or to admit the patient to the ICU will be taken by clinicians of every single participating center according to their guidelines.
Every device used, with oxygen flow values, FiO2, PEEP and ventilation mode (assisted/mechanical) will be noted in the CRF.
Antibiotic therapy and any pathogen responsible for pneumonia will be noted on the CRF.
Anesthesiologist will evaluate all the patients two hours after their return in the ward, and from the first to the fifth postoperative day. Anesthesiologists will be also on-call by the attending physician or the nursing staff every time patient's clinical conditions will need it.
Every patient will be followed (and will be enrolled in the study) until hospital discharge. Date of discharge will be noted in the CRF.
Moreover every enrolled patient will be followed-up at 30, 60 days and a year after hospital discharge, to verify the patients health status and to evaluate the incidence of re-hospitalization and mortality.
A form divided in three sections (pre/intra/postoperative period) will be used for data collection. Data will be collected on paper support and then entered in an electronic CRF.
Data will be anonymous. Every patient will be identified by a six number code: first three (from left to right) identify the participating center, the others identify the sequential number of enrollment.
The data insertion will be done by the investigators of every participating center, using personal username and password.
Data will be sent to the coordinator center where the data cleaning will be completed and statistical analysis will be performed with this timing:
after the 15 days enrolment period; after 4 months from the beginning of the study (30 days postoperative follow up); after 6 months from the beginning of the study (60 days postoperative follow up); after 16 months from the beginning of the study (1 year postoperative follow up) Every center will store its own paper CRF.
In the preoperative section will be recorded the patient's data about:
age, weight, height, sex; comorbidities (neurological, cardiovascular, metabolic, renal, muscular-skeletal) respiratory history positive for: previous pleuro-parenchymal diseases in the 30 days before surgery, previous chest, pleural or lung surgery, presence of pleural effusion; history of cigarettes smoking: active smoker (number of cigarettes), ex-smoker or not smoker; history of alcohol abuse (active potus, previous or abstinent); active cancer (excluding the diagnosis for surgery); SpO2, PaO2, PaO2/FiO2, PaCO2 when available; white cell number, hemoglobin and preoperative creatinine; ASA class; presence of nasogastric tube before surgery; presence of urinary catheter before surgery; blood products transfusion before surgery.
In the intraoperative section will be recorded the patient's data about:
type of surgery; type of anaesthesia (TIVA, balanced); type of analgesia (intravenous, epidural, perineural block); preoperative antibiotic prophylaxis; blood products transfusion; intraoperative fluid management (crystalloids Vs colloids, mL/Kg/h); type of ventilation (PCV/VCV); ventilation parameters (TV, Pins, PEEP, RR, FiO2); recruitment maneuvers (yes/no) (manuals, pressure controlled); intraoperative ventilatory problems ( (SpO2 < 90%, PaO2/FiO2 < 300, PaCO2 > 45 mmHg, increase of airways pressure over than 30 cmH2O, bronchospasm, needs of TV> 10 mL/Kg); hemorrhage or need of blood products transfusion; cardiovascular problems (hypotension, tachycardia, bradycardia, arrhythmia) and use of cardio/vasoactive drugs;
- length of surgery;
- use of qualitative or quantitative (TOF Watch) neuromuscular transmission monitoring systems use of neostigmine or sugammadex
- Final TOF ratio
In the postoperative section will be recorded the following data:
pain score at discharge from the operating room and up to the fifth postoperative day; needs of blood products transfusion in the postoperative period; stay of nasogastric tube;
- stay of urinary catheter;
- postoperative respiratory complications;
- postoperative non-respiratory complications (cardiovascular, renal, surgical, infections)
- needs of re-intubation in the postoperative period;
- needs of ventilatory support (non invasive ventilation, invasive ventilation) in the postoperative period; needs of ICU admission (planned, unplanned, cause, length of ICU stay); length of hospital stay; 30, 60 days and 1 year mortality (specify the cause).
Investigators are going to enroll 1500 patients undergoing elective major abdominal surgery, in a period of 15 days. Investigator decided to enroll all the patients in a limited period of time (as in LAS VEGAS [for more information...see www.euroanaesthesia.org., European Society of Anesthesiology (ESA) Clinical Trial Network]) and, if the sample size will not be sufficient, it will be possible to add 15 extra days. On the basis of works published by Squadrone et. al. (16%), Lawrence et.al.  (4,5%), Hall et. al.  (15%), Mitchell et.al.  (11%) and Canet et. al. (7,2%) , the hypothesis was that the incidence of primary outcome (PaO2 /FiO2≤ 300) will be 7%.
The sample size has been calculated using alpha = 0,05 (2-tailed test) and CI of 95%.
The result of this calculation is a sample size of 1422. Investigators decided to enroll 1500 patients because this way our population will be heterogeneous and because of possible deviations from the protocol.
The statistic analysis will include:
- descriptive statistics of all the collected data (average, median, standard deviation, interquartile range, minimum and maximum for the continuous variables; relative and absolute frequency for the qualitative variables
- interdependence between two or more variables (if present)
- Statistic comparison between continuous variables, using t-Student test (if the variable has a normal distribution) or non-parametric tests.
- Comparison between qualitative variables, using Chi-square test
- Odds ratio
- Logistic regression
- The study will include the possibility to perform non-planned analyses, if useful.
The data will be saved on an electronic support, using the Softwares Epi info 2002 (CDC), SPSS11.0 (SPSS) and STATA 9.0 (STATA), when appropriate.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01701908
|Contact: Giorgio Della Rocca, Professor||+39 0432 email@example.com|
|Desenzano Hospital||Not yet recruiting|
|Desenzano del Garda, Brescia, Italy, 25015|
|Contact: Nicola Petrucci firstname.lastname@example.org|
|Principal Investigator: Nicola Petrucci, MD|
|C.E.S.A.T. S. Pietro Igneo Hospital||Not yet recruiting|
|Fucecchio, Firenze, Italy, 50054|
|Contact: Emanuele Mori email@example.com|
|Principal Investigator: Emanuele Mori, MD|
|San Gerardo Hospital||Not yet recruiting|
|Monza, Monza e Brianza, Italy, 20900|
|Contact: Roberto Fumagalli firstname.lastname@example.org|
|Principal Investigator: Roberto Fumagalli, MD|
|Ceccarini Hospital||Not yet recruiting|
|Riccione, Rimini, Italy, 47838|
|Contact: Alessandro Gatta email@example.com|
|Principal Investigator: Alessandro Gatta, MD|
|Institute For Cancer Research And Treatment||Not yet recruiting|
|Candiolo, Torino, Italy, 10060|
|Contact: Francesco Bona firstname.lastname@example.org|
|Principal Investigator: Francesco Bona, MD|
|S.Luigi Gonzaga Hospital||Not yet recruiting|
|Orbassano, Torino, Italy, 10043|
|Contact: Augusto Tempia email@example.com|
|Principal Investigator: Augusto Tempia, MD|
|S. Valentino Hospital|
|Montebelluna, Treviso, Italy, 31044|
|Department of Anesthesia and Intensive Care Medicine of the Medical School of the University of Udine (Coordinating center)||Not yet recruiting|
|Udine, UD, Italy, 33100|
|Contact: Giorgio Della Rocca, Professor +39 0432 559501 firstname.lastname@example.org|
|Principal Investigator: Giorgio Della Rocca, MD, Professor, PI|
|Orlandi Hospital||Not yet recruiting|
|Bussolengo, Verona, Italy, 37012|
|Contact: Plinio Calligaro email@example.com|
|Principal Investigator: Plinio Calligaro, MD|
|Italian National Research Centres On Aging||Not yet recruiting|
|Contact: Gabriella Bettelli firstname.lastname@example.org|
|Principal Investigator: Gabriella Bettelli, MD|
|Cardinal Massaia Hospital||Not yet recruiting|
|Asti, Italy, 14100|
|Contact: Agostino Roasio email@example.com|
|Principal Investigator: Agostino Roasio, MD|
|Bari Hospital||Not yet recruiting|
|Bari, Italy, 70131|
|Contact: Salvatore Grasso firstname.lastname@example.org|
|Principal Investigator: Salvatore Grasso, MD|
|S.Orsola-Malpighi Hospital||Not yet recruiting|
|Bologna, Italy, 40138|
|Contact: Maurizio Fusari email@example.com|
|Principal Investigator: Maurizio Fusari, MD|
|Catania Hospital (Policlinico)||Not yet recruiting|
|Catania, Italy, 95123|
|Contact: Antonino Gullo firstname.lastname@example.org|
|Principal Investigator: Antonino Gullo, MD|
|Cannizzaro Emergency Hospital||Not yet recruiting|
|Catania, Italy, 95126|
|Contact: Luigi Vicari email@example.com|
|Principal Investigator: Luigi Vicari, MD|
|S. Anna Hospital||Not yet recruiting|
|Ferrara, Italy, 44124|
|Contact: Teresa Matarazzo firstname.lastname@example.org|
|Principal Investigator: Teresa Matarazzo, MD|
|Mugello Hospital||Not yet recruiting|
|Firenze, Italy, 50122|
|Contact: Vieri Parrini email@example.com|
|Principal Investigator: Vieri Parrini, MD|
|S. Maria Nuova Hospital||Not yet recruiting|
|Firenze, Italy, 50123|
|Contact: Antonio Franco firstname.lastname@example.org|
|Principal Investigator: Antonio Franco, MD|
|Careggi Hospital||Not yet recruiting|
|Firenze, Italy, 50134|
|Contact: Raffaele De Gaudio email@example.com|
|Principal Investigator: Raffaele De Gaudio, MD|
|IRCCS San Martino||Not yet recruiting|
|Genova, Italy, 16132|
|Contact: Luigi Spagnolo firstname.lastname@example.org|
|Principal Investigator: Luigi Spagnolo, MD|
|Fazzi Hospital||Not yet recruiting|
|Lecce, Italy, 73100|
|Contact: Luigi Fuggiano email@example.com|
|Principal Investigator: Luigi Fuggiano, MD|
|Macerata Hospital||Not yet recruiting|
|Macerata, Italy, 62100|
|Contact: Giuseppe Tappata giuseppe.tappatà@sanita.marche.it|
|Principal Investigator: Giuseppe Tappata, MD|
|Mantova Hospital||Not yet recruiting|
|Mantova, Italy, 46100|
|Contact: Vincenzo Sgarioto firstname.lastname@example.org|
|Principal Investigator: Vincenzo Sgarioto, MD|
|IRCCS S. Raffaele, Milano||Not yet recruiting|
|Milano, Italy, 20132|
|Contact: Elena Bignami, MD email@example.com|
|Principal Investigator: Elena Bignami, MD|
|Sub-Investigator: Giacomo Moniti, MD|
|European Institute Of Oncology||Not yet recruiting|
|Milano, Italy, 20141|
|Contact: Daniele Sances firstname.lastname@example.org|
|Principal Investigator: Daniele Sances, MD|
|San Paolo Hospital, University Of Milano||Not yet recruiting|
|Milano, Italy, 20142|
|Contact: Concezione Tommasino email@example.com|
|Principal Investigator: Tommasino Concezione, MD|
|Niguarda Ca' Granda, Milano||Not yet recruiting|
|Milano, Italy, 20162|
|Contact: Ines Arpino firstname.lastname@example.org|
|Principal Investigator: Ines Arpino, MD|
|Federico II Hospital||Not yet recruiting|
|Napoli, Italy, 80131|
|Contact: Rosalba Tufano email@example.com|
|Principal Investigator: Rosalba Tufano, MD|
|Major Charity Hospital||Not yet recruiting|
|Novara, Italy, 28100|
|Contact: Valeria Viarengo firstname.lastname@example.org|
|Principal Investigator: Valeria Viarengo, MD|
|IRCCS San Matteo Hospital||Not yet recruiting|
|Pavia, Italy, 27100|
|Contact: Antonio Braschi email@example.com|
|Principal Investigator: Antonio Braschi, MD|
|S.Maria of Mercy Hospital||Not yet recruiting|
|Perugia, Italy, 06156|
|Contact: Paola Fabbricini firstname.lastname@example.org|
|Principal Investigator: Paola Fabbricini, MD|
|Nuovo Santa Chiara Hospital||Not yet recruiting|
|Pisa, Italy, 56100|
|Contact: Francesco Forfori email@example.com|
|Principal Investigator: Francesco Forfori, MD|
|Prato Hospital||Not yet recruiting|
|Prato, Italy, 59100|
|Contact: Guglielmo Consales firstname.lastname@example.org|
|Principal Investigator: Guglielmo Consales, MD|
|Umberto I, "Sapienza", University of Rome||Not yet recruiting|
|Rome, Italy, 00161|
|Contact: Franco Ruberto email@example.com|
|Principal Investigator: Franco Ruberto, MD|
|Sub-Investigator: Maurizio Marandola, MD|
|Sub-Investigator: Sergio Gazzanelli, MD|
|Sub-Investigator: Di Marco Pierangelo, MD|
|Catholic University Hospital A. Gemelli||Not yet recruiting|
|Rome, Italy, 00168|
|Contact: Paolo Primieri firstname.lastname@example.org|
|Principal Investigator: Paolo Primieri, MD|
|San Giovanni Battista Hospital||Not yet recruiting|
|Torino, Italy, 10126|
|Contact: Elisabetta Cerutti email@example.com|
|Principal Investigator: Elisabetta Cerutti, MD|
|S.Maria di Ca' Foncello||Not yet recruiting|
|Treviso, Italy, 31100|
|Contact: Roberto Nani firstname.lastname@example.org|
|Principal Investigator: Roberto Nani, MD|
|Principal Investigator:||Giorgio Della Rocca, Professor||University of Udine|